Nothing Special   »   [go: up one dir, main page]

AU1071301A - Pharmaceutical compounds - Google Patents

Pharmaceutical compounds

Info

Publication number
AU1071301A
AU1071301A AU10713/01A AU1071301A AU1071301A AU 1071301 A AU1071301 A AU 1071301A AU 10713/01 A AU10713/01 A AU 10713/01A AU 1071301 A AU1071301 A AU 1071301A AU 1071301 A AU1071301 A AU 1071301A
Authority
AU
Australia
Prior art keywords
pharmaceutical compounds
pharmaceutical
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU10713/01A
Inventor
Samantha Jayne Ambler
Stephen Richard Baker
Barry Peter Clark
Darrell Stephen Coleman
Robert James Foglesong
John Goldsworthy
Jian Eric Hong
Gunnar Erik Junior Jagdmann
Kirk Willis Johnson
Ann Elizabeth Kingston
William Martin Owton
Jeffrey Michael Schkeryantz
Darryle Darwin Schoepp
Michael Scott Vannieuwenhze
Mohammad Sadegh Zia-Ebrahimi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU1071301A publication Critical patent/AU1071301A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU10713/01A 1999-11-01 2000-10-19 Pharmaceutical compounds Abandoned AU1071301A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16290099P 1999-11-01 1999-11-01
US60162900 1999-11-01
PCT/US2000/026261 WO2001032632A2 (en) 1999-11-01 2000-10-19 Pharmaceutically active 4-substituted pyrimidine derivatives

Publications (1)

Publication Number Publication Date
AU1071301A true AU1071301A (en) 2001-05-14

Family

ID=22587589

Family Applications (1)

Application Number Title Priority Date Filing Date
AU10713/01A Abandoned AU1071301A (en) 1999-11-01 2000-10-19 Pharmaceutical compounds

Country Status (7)

Country Link
EP (1) EP1230225A2 (en)
AR (1) AR026275A1 (en)
AU (1) AU1071301A (en)
CO (1) CO5261605A1 (en)
PE (1) PE20010854A1 (en)
SV (1) SV2002000205A (en)
WO (1) WO2001032632A2 (en)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429207B1 (en) 1997-11-21 2002-08-06 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
EP1408980A4 (en) 2001-06-21 2004-10-20 Ariad Pharma Inc Novel quinazolines and uses thereof
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
AU2003242252A1 (en) 2002-06-07 2003-12-22 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
US7423044B2 (en) 2002-09-05 2008-09-09 Wyeth Pyrimidine derivatives useful in the treatment of insulin resistance and hyperglycemia
TW200410975A (en) * 2002-09-26 2004-07-01 Nihon Nohyaku Co Ltd New pesticide and method for using it, new substituted thienopyrimidine derivative, its intermediate, and method for producing it
US7196106B2 (en) 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use
AU2003293006A1 (en) * 2002-11-22 2004-06-18 Japan Tobacco Inc. Fused bicyclic nitrogen-containing heterocycles
AU2003288994A1 (en) * 2002-12-10 2004-06-30 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compounds and medicinal use thereof
ES2279361T3 (en) 2003-04-16 2007-08-16 F. Hoffmann-La Roche Ag DERIVATIVES OF (6- (FENOXI) -PIRIDO-3,4-DIPIRIMIDIN-2-IL) -AMINE AS INHIBITORS OF P38 KINASA FOR THE TREATMENT OF INFLAMMATORY STATES SUCH AS REUMATOID ARTHRITIS.
EP1620408A2 (en) 2003-04-16 2006-02-01 F. Hoffmann-La Roche Ag Quinazoline compounds
US7300932B2 (en) 2003-08-07 2007-11-27 Japan Tobacco Inc. Pyrrolo[1,2-b]pyridazine derivatives
WO2005016925A1 (en) * 2003-08-14 2005-02-24 Pfizer Limited Azaquinazoline derivatives
TW200530235A (en) 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
US20070197510A1 (en) * 2004-03-10 2007-08-23 Kazuyuki Ohmoto Nitriles and medicinal compositions containing the same as the active ingredient
US7793137B2 (en) 2004-10-07 2010-09-07 Cisco Technology, Inc. Redundant power and data in a wired data telecommunincations network
US7598259B2 (en) 2004-06-15 2009-10-06 Schering Corporation mGluR1 antagonists as therapeutic agents
AR049300A1 (en) * 2004-06-15 2006-07-12 Schering Corp MGLUR1 ANTAGONIST TRICICLIC COMPOUNDS AS THERAPEUTIC AGENTS
CA2573999A1 (en) 2004-07-16 2006-04-06 Sunesis Pharmaceuticals, Inc. Thienopyrimidines useful as aurora kinase inhibitors
US8283354B2 (en) 2004-09-02 2012-10-09 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
US7928107B2 (en) 2004-09-02 2011-04-19 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
DE602005015231D1 (en) * 2004-09-02 2009-08-13 Vertex Pharma CHINAZOLINS SUITABLE AS ION CHANNEL MODULATORS
GB0420719D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US20060128710A1 (en) * 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
ES2552804T3 (en) 2005-05-04 2015-12-02 Evotec Ag Condensed heterocyclic compounds, and their compositions and uses
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
WO2007030582A2 (en) * 2005-09-09 2007-03-15 Bristol-Myers Squibb Company Acyclic ikur inhibitors
WO2007070872A1 (en) 2005-12-15 2007-06-21 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
HUP0501170A2 (en) * 2005-12-20 2007-09-28 Richter Gedeon Nyrt 2-heteroaryl-3-phenyl-thieno[2,3-b]pyridines, process for their preparation, their use and pharmaceutical compositions containing them
US20100022521A1 (en) * 2005-12-20 2010-01-28 Hansa Metallwerke Ag Compounds
HUP0501168A3 (en) * 2005-12-20 2007-10-29 Richter Gedeon Nyrt 2-(acyl, oxycarbonyl or aminocarbonyl)-3-phenyl-thieno[2,3-b]pyridines, process for their preparation, their use and pharmaceutical composition containing them
US20090149495A1 (en) * 2005-12-20 2009-06-11 Katalin Nogradi Compounds
EP2345652A1 (en) 2005-12-21 2011-07-20 Abbott Laboratories Antiviral compounds
DE602006015861D1 (en) 2005-12-21 2010-09-09 Abbott Lab ANTIVIRAL CONNECTIONS
US7910595B2 (en) 2005-12-21 2011-03-22 Abbott Laboratories Anti-viral compounds
US7915411B2 (en) 2005-12-21 2011-03-29 Abbott Laboratories Anti-viral compounds
AR059898A1 (en) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv DERIVATIVES OF 3-CIANO-PIRIDONA 1,4-DISUSTITUTED AND ITS USE AS ALLOSTERIC MODULATORS OF MGLUR2 RECEIVERS
DE102006012251A1 (en) * 2006-03-15 2007-11-08 Grünenthal GmbH Substituted 4-aminoquinazoline derivatives and their use for the preparation of medicaments
EP1921070A1 (en) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation
PL2083811T3 (en) 2006-11-22 2017-05-31 Clinical Research Associates, Llc Methods of treating down's syndrome, fragile x syndrome and autism
WO2008133753A2 (en) 2006-12-20 2008-11-06 Abbott Laboratories Anti-viral compounds
MX2009007610A (en) 2007-02-06 2009-07-24 Boehringer Ingelheim Int Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof.
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
US20090209536A1 (en) * 2007-06-17 2009-08-20 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
ES2380165T3 (en) 2007-08-02 2012-05-09 Recordati Ireland Limited New heterocyclic compounds as mGlu5 antagonists
CN101848893B (en) 2007-09-14 2012-06-06 奥梅-杨森制药有限公司 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
PL2203439T3 (en) 2007-09-14 2011-06-30 Addex Pharmaceuticals Sa 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-ý1, 4'¨bipyridinyl-2'-ones
PT2245026E (en) 2008-02-07 2012-10-15 Boehringer Ingelheim Int Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production
EA019183B1 (en) 2008-05-13 2014-01-30 Астразенека Аб Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline
JP5539351B2 (en) 2008-08-08 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cyclohexyloxy-substituted heterocycles, medicaments containing these compounds, and methods for producing them
ES2439291T3 (en) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. 3-Azabicyclo [3.1.0] hexyl derivatives as modulators of metabotropic glutamate receptors
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
JP5539376B2 (en) * 2008-11-19 2014-07-02 エボテック （ユーエス） インコーポレイテッド 6,7-Dihydro-5H-pyrrolo [3,4-D] pyrimidin-4-yl] quinolin-3-ylamine compounds useful as FAAH modulators and uses thereof
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
PE20120106A1 (en) * 2008-12-09 2012-02-20 Gilead Sciences Inc TOLL TYPE RECEIVER MODULATORS
US20100317630A1 (en) 2009-02-04 2010-12-16 Recordati Ireland Limited Novel heterocyclic compounds as mglu5 antagonists
PT2430022E (en) 2009-05-12 2013-12-26 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
NZ596053A (en) 2009-05-12 2013-05-31 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US20120028931A1 (en) 2009-09-14 2012-02-02 Recordati Ireland Limited Heterocyclic m-glu5 antagonists
WO2011106276A1 (en) * 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US20110294879A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
MX2013000300A (en) * 2010-07-09 2013-02-27 Recordati Ireland Ltd Novel spiroheterocyclic compounds as mglu5 antagonists.
WO2012009646A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
CA2813437A1 (en) 2010-10-08 2012-04-12 Abbvie Inc. Furo[3,2-d]pyrimidine compounds
WO2012054724A1 (en) 2010-10-21 2012-04-26 Massachusetts Institute Of Technology Methods of treating seizure disorders
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2649069B1 (en) 2010-11-08 2015-08-26 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
CN110194748A (en) 2012-01-13 2019-09-03 艾森生物科学公司 Heterocyclic compound and its purposes as anticarcinogen
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
US9586965B2 (en) 2012-01-13 2017-03-07 Acea Biosciences Inc. Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
TWI499591B (en) 2013-01-11 2015-09-11 Lilly Co Eli Bicyclic pyrimidine compounds
TW201520219A (en) * 2013-03-12 2015-06-01 Lilly Co Eli Imidazo pyridine compounds
TW201500356A (en) * 2013-04-12 2015-01-01 Lilly Co Eli Dihydropyrido pyrimidine compounds
JO3368B1 (en) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
WO2015006754A2 (en) 2013-07-11 2015-01-15 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
JO3367B1 (en) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
HUE053734T2 (en) 2014-01-21 2021-07-28 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators of metabotropic glutamatergic receptor subtype 2 and their use
RS61334B1 (en) 2014-01-21 2021-02-26 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators of metabotropic glutamatergic receptor subtype 2 and their use
EP3134405B1 (en) 2014-04-25 2019-08-28 Pfizer Inc Heteroaromatic compounds and their use as dopamine d1 ligands
WO2017004405A1 (en) * 2015-07-01 2017-01-05 Northwestern University Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity
CA2993312A1 (en) 2015-07-23 2017-01-26 Takeda Pharmaceutical Company Limited 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists
KR20180067584A (en) 2015-10-09 2018-06-20 아세아 테라퓨틱스 인코포레이티드 PHARMACEUTICALS, PHYSICAL FORM AND COMPOSITIONS OF PYRROLOPYRIMIDINE KINASE INHIBITORS AND METHODS FOR THEIR PREPARATION
GB201700814D0 (en) 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
WO2018184206A1 (en) 2017-04-07 2018-10-11 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
EP4151616A4 (en) * 2021-04-26 2023-12-20 Mitsubishi Gas Chemical Company, Inc. Compound and method for producing same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1582407A (en) * 1977-06-07 1981-01-07 Worcester Controls Uk Ltd Annular seals
US5034393A (en) * 1989-07-27 1991-07-23 Dowelanco Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives
PT100905A (en) * 1991-09-30 1994-02-28 Eisai Co Ltd BICYCLE HYGIENEOUS HETEROCYCLIC COMPOUNDS CONTAINING BENZENE, CYCLOHEXAN OR PYRIDINE AND PYRIMIDINE, PYRIDINE OR IMIDAZOLE SUBSTITUTES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9613021D0 (en) * 1996-06-21 1996-08-28 Pharmacia Spa Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
GB9823845D0 (en) * 1998-11-02 1998-12-23 Lilly Co Eli Pharmaceutical compounds
DE19904710A1 (en) * 1999-02-05 2000-08-10 Aventis Pharma Gmbh Substituted 4-amino-2-aryl-tetrahydroquinazolines, their preparation, their use and pharmaceutical compositions containing them
SE9903290D0 (en) * 1999-09-15 1999-09-15 Astra Pharma Prod Novel compounds

Also Published As

Publication number Publication date
SV2002000205A (en) 2002-06-07
WO2001032632A3 (en) 2001-11-08
WO2001032632A2 (en) 2001-05-10
AR026275A1 (en) 2003-02-05
PE20010854A1 (en) 2001-08-28
EP1230225A2 (en) 2002-08-14
CO5261605A1 (en) 2003-03-31

Similar Documents

Publication Publication Date Title
AU1071301A (en) Pharmaceutical compounds
AU5413600A (en) Compounds
AU5259100A (en) Medicament
AU1278701A (en) Novel compounds
AU1225000A (en) Combined pharmaceutical estrogen-androgen-progestin
AU3556400A (en) Pharmaceutical compositions
AU4328800A (en) Pharmaceutical formulation
AU6715600A (en) Pharmaceutical formulations
IL145632A0 (en) Pharmaceutical compounds
AU1746401A (en) Compounds
AU3997700A (en) Anti-first-pass effect compounds
AU6032100A (en) New compounds
AU6460400A (en) Pharmaceutical compositions
GB9916434D0 (en) Pharmaceutical compounds
AU1645700A (en) Oenothein medicaments
AU5722900A (en) Pharmaceutical compounds
AU4977300A (en) Pharmaceutical formulations
AU6460200A (en) Pharmaceutical compositions
AU1385801A (en) Pharmaceutical formulations
AU6480299A (en) Pharmaceutical compounds
GB9903784D0 (en) Pharmaceutical compounds
AU6460100A (en) Pharmaceutical compositions
AU6460300A (en) Pharmaceutical compositions
AU3839900A (en) Pharmaceutical formulation
GB2373499B (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase